Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)

• Company Description    Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy. Number of Employees: 31,500

• Price / Volume Information    Yesterday's Closing Price: $376.04 Daily Weekly Monthly 20 Day Moving Average: 2,163,029 shares Shares Outstanding: 539.71 (millions) Market Capitalization: $202,951.80 (millions) Beta: 0.41 52 Week High: $391.29 52 Week Low: $269.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.58% 5.80% 12 Week 8.60% 5.63% Year To Date 14.89% 4.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE AMGEN CENTER DRIVE - THOUSAND OAKS,CA 91320 USA ph: 805-447-1000 fax: 805-447-1010 investor.relations@amgen.com http://www.amgen.com

• General Corporate Information    Officers Robert A. Bradway - Chief Executive Officer; Chairman of the Board and Peter H. Griffith - Executive Vice President andChief Financial Office Matthew C. Busch - Vice President; Finance andChief Accounting Office Wanda M. Austin - Director Michael V. Drake - Director Peer Information Amgen Inc. (CORR.) Amgen Inc. (RSPI) Amgen Inc. (CGXP) Amgen Inc. (BGEN) Amgen Inc. (GTBP) Amgen Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 031162100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 539.71 Most Recent Split Date: 11.00 (2.00:1) Beta: 0.41 Market Capitalization: $202,951.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.68% Current Fiscal Quarter EPS Consensus Estimate: $5.71 Indicated Annual Dividend: $10.08 Current Fiscal Year EPS Consensus Estimate: $22.31 Payout Ratio: 0.46 Number of Estimates in the Fiscal Year Consensus: 13.00 Change In Payout Ratio: 0.01 Estmated Long-Term EPS Growth Rate: 4.43% Last Dividend Paid: 05/15/2026 - $2.52 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: 16.86 Trailing 12 Months: 17.02 PEG Ratio: 3.80 Price Ratios Price/Book: 22.08 Price/Cash Flow: 11.12 Price / Sales: 5.45 EPS Growth vs. Year Ago Period: 5.10% vs. Previous Quarter: -2.65% Sales Growth vs. Year Ago Period: 5.76% vs. Previous Quarter: -12.65% ROE 06/30/26 - - 03/31/26 - 137.41 12/31/25 - 148.37 ROA 06/30/26 - - 03/31/26 - 13.28 12/31/25 - 13.23 Current Ratio 06/30/26 - - 03/31/26 - 1.26 12/31/25 - 1.14 Quick Ratio 06/30/26 - - 03/31/26 - 1.01 12/31/25 - 0.90 Operating Margin 06/30/26 - - 03/31/26 - 32.21 12/31/25 - 32.21 Net Margin 06/30/26 - - 03/31/26 - 20.96 12/31/25 - 20.98 Pre-Tax Margin 06/30/26 - - 03/31/26 - 24.41 12/31/25 - 24.42 Book Value 06/30/26 - - 03/31/26 - 17.03 12/31/25 - 16.08 Inventory Turnover 06/30/26 - - 03/31/26 - 1.86 12/31/25 - 1.86 Debt-to-Equity 06/30/26 - - 03/31/26 - 5.65 12/31/25 - 5.78 Debt-to-Capital 06/30/26 - - 03/31/26 - 84.95 12/31/25 - 85.24

Powered by Zacks Investment Research ©